MaxCyte Inc expected to post a loss of 10 cents a share - Earnings Preview

MaxCyte

04/08/2025 21:09

MaxCyte Inc MXCT.OQ MXCT.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The Rockville Maryland-based  company is expected to report a 8.6% decrease in revenue to $9.528 million from $10.43 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for MaxCyte Inc is for a loss of 10 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 4.5% in the last three months. ‚Äč

Wall Street's median 12-month price target for MaxCyte Inc is $6.50, about 68.6% above its last closing price of $2.04

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.10
-0.10
Met
4.8
Dec. 31 2025
-0.11
-0.12
-0.10
Beat
18
Sep. 30 2024
-0.12
-0.12
-0.11
Beat
10.8‚Äč
Jun. 30 2024
-0.13
-0.13
-0.09
Beat
28.9
‚Äč‚ÄčMar. 31 2024
-0.13
-0.13
-0.09
Beat
30.8
Dec. 31 2023
-0.07
-0.07
-0.05
Beat
30.6‚Äč
Sep. 30 2023
-0.10
-0.10
-0.11
Missed
-7.8
Jun. 30 2023
-0.10
-0.10
-0.10
Met
-4.2

This summary was machine generated August 4 at 20:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)